Inclusion Criteria:

          -  Patients must be newly diagnosed with localized primary CNS NGGCT (Stratum 1) or
             localized primary CNS germinoma (Stratum 2); germ cell tumors located in the
             suprasellar, pineal, bifocal (pineal + suprasellar) and ventricles are eligible;
             tumors present in the above mentioned locations and with unifocal parenchymal
             extension are eligible

               -  Stratum 1(NGGCT): Patients must have one of the following criteria:

                    -  Patients with serum and/or CSF hCGbeta > 100 mIU/mL or any elevation of
                       serum and/or CSF alpha-fetoprotein (AFP) > 10 ng/mL or greater than the
                       institutional normal are eligible, irrespective of biopsy results

                    -  Patients with any of the following elements on biopsy/resection are
                       eligible, irrespective of serum and/or CSF hCGbeta and AFP levels:
                       endodermal sinus tumor (yolk sac), embryonal carcinoma, choriocarcinoma,
                       malignant/immature teratoma, and mixed GCT with malignant GCT elements

               -  Stratum 2 (Germinoma): Patients must have both serum and CSF markers obtained
                  (unless obtaining CSF is medically contraindicated) and must have one of the
                  following criteria to be eligible:

                    -  Patients with institutional normal AFP (or =< 10 ng/mL if no institutional
                       normal exists) in both serum and CSF (unless medically contraindicated) AND
                       hCGbeta 5 to =< 50 mIU/mL in serum and/or CSF (unless medically
                       contraindicated) (only 1 is required to be elevated) are eligible; no
                       histologic confirmation required

                    -  Patients with bifocal (pineal + suprasellar) involvement or pineal lesion
                       with diabetes insipidus (D1) AND hCGbeta =< 100 mIU/mL in serum and/or CSF
                       AND institutional normal AFP (or =< 10 ng/mL if no institutional normal
                       exists) in both serum and CSF (unless medically contraindicated) are
                       eligible; no histologic confirmation required

                    -  Patients with histologically confirmed germinoma or germinoma mixed with
                       mature teratoma and hCGbeta =< 100 mIU/mL in serum and/or CSF and
                       institutional normal AFP (or =< 10 ng/mL if no institutional normal exists)
                       in both serum and CSF (unless medically contraindicated) are eligible

          -  All patients must have a cranial MRI with and without gadolinium at diagnosis/prior to
             enrollment; if surgical resection is performed, patients must have pre-operative and
             post-operative cranial MRI with and without gadolinium; the post-operative brain MRI
             should be obtained within 72 hours of surgery; if patient has a biopsy only,
             post-operative cranial MRI is recommended but not required; all patients must have a
             spine MRI with gadolinium obtained at diagnosis/prior to enrollment; Note: if the
             spine study is performed for the first time after surgical resection or biopsy, it is
             recommended to be obtained with and without gadolinium

          -  Lumbar CSF must be obtained prior to study enrollment unless medically
             contraindicated; if a patient undergoes surgery and lumbar CSF cannot be obtained at
             this time, then it should be performed at least 10 days following surgery before study
             enrollment; false positive cytology can occur within 10 days of surgery; Note:
             patients with positive CSF cytology obtained prior to 10 days after surgery may have
             cytology repeated to determine eligibility

          -  Patients must have CSF tumor markers obtained prior to enrollment unless medically
             contraindicated; ventricular CSF obtained at the time of CSF diversion procedure (if
             performed) is acceptable for tumor markers but lumbar CSF is preferred; in case CSF
             diversion and biopsy/surgery are combined, CSF tumor markers should be collected first

          -  Patients must be enrolled on ALTE07C1 prior to enrollment on ACNS1123; patients must
             be enrolled within 31 days of definitive diagnostic surgery (day 0) or clinical
             diagnosis

          -  Peripheral absolute neutrophil count (ANC) >= 1,000/uL

          -  Platelet count >= 100,000/uL (transfusion independent)

          -  Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions)

          -  Creatinine clearance or radioisotope glomular filtration rate (GFR) >= 70 mL/min/1.73
             m^2 OR serum creatinine based on age/gender as follows:

               -  0.8 mg/dL (2 to < 6 years of age)

               -  1.0 mg/dL (6 to < 10 years of age)

               -  1.2 mg/dL (10 to < 13 years of age)

               -  1.5 mg/dL (male) and 1.4 mg/dL (female) (13 to < 16 years of age)

               -  1.7 mg/dL (male) and 1.4 mg/dL (female) (>= 16 years of age)

          -  Total bilirubin =< 1.5 times upper limit of normal (ULN) for age

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and
             serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5
             times ULN

          -  Patients with seizure disorder may be enrolled if well controlled

          -  Patients must not be in status, coma, or assisted ventilation prior to study
             enrollment

        Exclusion Criteria:

          -  Patients with mature teratoma or completely resected immature teratoma with normal
             tumor markers are not eligible

          -  Patients with tumors located outside the ventricles (basal ganglia, thalamus) are not
             eligible

          -  Patients with metastatic disease by cranial or spinal MRI evaluation or CSF cytology
             (unless medically contraindicated) are not eligible

          -  Patients must not have received any prior tumor-directed therapy other than surgical
             intervention and corticosteroids

          -  Female patients who are pregnant are ineligible

          -  Lactating females are not eligible unless they have agreed not to breastfeed their
             infants

          -  Female patients of childbearing potential are not eligible unless a negative pregnancy
             test result has been obtained

          -  Sexually active patients of reproductive potential are not eligible unless they have
             agreed to use an effective contraceptive method for the duration of their study
             participation

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent

          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute
             (NCI) requirements for human studies must be met